Galaxy Digital Inc. Class A Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.54 (market cap $3.83B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.2× Galaxy Digital Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Galaxy Digital Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GLXY | HNGE | |
|---|---|---|
Market Cap | $3.83B | $8.48B |
Volume | 5,859,599 | 879,799 |
Sector | Financials | Health |
52-Week High | $42.86 | $105.14 |
52-Week Low | $16.84 | $31.17 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $6.28B | $8.10B |
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →